Lantern Pharma Inc. (LTRN)
Lantern Pharma develops cancer drugs using an artificial intelligence platform to match them with suitable patients. It last closed at $0.36 on Nov 17, down 6.17% on the day. LTRN last reported earnings on Fri, Aug 14, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From LTRN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 17). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Technical Analysis
The stock is 57% below its 20 day and 154% below its 50 day average. It is 528% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $0.36, and the nearest resistance the Pivot at $0.38.
| RSI (14) | 23.46 | Oversold below 30 | Oversold |
| MACD | -0.15 | Above its signal line | Bullish |
| Stochastic | 1.4 | Near the bottom of its range | Oversold |
| ADX (14) | 48.4 | Strong downtrend | |
| Williams %R | -100.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -160.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −39.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.09 | Typical daily range, 25.5% of price |
| RSI (14) | 22.99 | Oversold below 30 | Oversold |
| MACD | -0.67 | Below its signal line | Bearish |
| Stochastic | 1.1 | Near the bottom of its range | Oversold |
| ADX (14) | 37.5 | Trending down | |
| Williams %R | -100.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -100.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −78.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.41 | Typical daily range, 112.0% of price |
What happened before
See how LTRN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LTRN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in LTRN in the last 90 days.
LTRN Institutional Ownership
Full report →- ●16 buying vs 18 selling
- ▲Held by funds +6.4 pts
- ▲Funds holding +3
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 43 | 40 | +7.5% |
| In funds' top 10 | 1 | 2 | −50.0% |
| Held by funds | 24.5% | 18.2% | +6.4 pts |
| New / increased | 9 / 7 | 12 / 10 | −27.3% |
| Reduced / sold out | 12 / 6 | 8 / 7 | +20.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LTRN is in one of them and how their past LTRN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LTRN in an article yet. Here's the latest on the wider market.
About Lantern Pharma
Lantern Pharma is a Dallas, Texas company that develops cancer drugs. It uses an artificial intelligence platform, called RADR, to analyze large sets of medical and research data and to identify the patients most likely to respond to each drug. Its pipeline includes several small molecule candidates in clinical trials for solid tumors and blood cancers, and it also works on reviving older compounds that were previously halted. The company plans to offer some of its AI tools to other researchers and drug developers.
- Headquarters
- Dallas, TX

